Literature DB >> 15934846

Immunotherapy and immunoprevention of cancer: where do we stand?

Federica Cavallo1, Claudia Curcio, Guido Forni.   

Abstract

Although evolution has shaped the immune system to control microbial invasions, this does not necessarily mean that the immune system can not be triggered to eliminate tumour cells. The exploitation of the terrific potential of the immune system to recognise cell alterations and to selectively destroy large populations of neoplastic cells is a possibility made even more attractive by the advances in our understanding of the immune mechanisms and our ability to manipulate them. This review summarises the state of the different immunotherapy strategies available or in development today, and examines the future developments that hold out the promise of an effective control of cancer growth.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15934846     DOI: 10.1517/14712598.5.5.717

Source DB:  PubMed          Journal:  Expert Opin Biol Ther        ISSN: 1471-2598            Impact factor:   4.388


  2 in total

Review 1.  Dendritic cell-based cancer immunotherapy for colorectal cancer.

Authors:  Mikio Kajihara; Kazuki Takakura; Tomoya Kanai; Zensho Ito; Keisuke Saito; Shinichiro Takami; Shigetaka Shimodaira; Masato Okamoto; Toshifumi Ohkusa; Shigeo Koido
Journal:  World J Gastroenterol       Date:  2016-05-07       Impact factor: 5.742

2.  CCR3, CCR4, CCR5, and CXCR3 expression in peripheral blood CD4+ lymphocytes in gastric cancer patients.

Authors:  Alireza Andalib; Hassan Doulabi; Mohammad Reza Maracy; Abbas Rezaei; Seyed Javad Hasheminia
Journal:  Adv Biomed Res       Date:  2013-03-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.